KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Total Current Liabilities (2016 - 2025)

Alnylam Pharmaceuticals (ALNY) has disclosed Total Current Liabilities for 16 consecutive years, with $1.6 billion as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Total Current Liabilities rose 27.43% year-over-year to $1.6 billion, compared with a TTM value of $1.6 billion through Sep 2025, up 27.43%, and an annual FY2024 reading of $1.2 billion, up 22.58% over the prior year.
  • Total Current Liabilities was $1.6 billion for Q3 2025 at Alnylam Pharmaceuticals, up from $1.3 billion in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $1.6 billion in Q3 2025 and bottomed at $494.8 million in Q1 2021.
  • Average Total Current Liabilities over 5 years is $888.2 million, with a median of $788.6 million recorded in 2023.
  • The sharpest move saw Total Current Liabilities surged 46.06% in 2021, then grew 10.38% in 2022.
  • Year by year, Total Current Liabilities stood at $695.7 million in 2021, then rose by 10.38% to $767.9 million in 2022, then grew by 26.03% to $967.8 million in 2023, then increased by 22.58% to $1.2 billion in 2024, then surged by 31.12% to $1.6 billion in 2025.
  • Business Quant data shows Total Current Liabilities for ALNY at $1.6 billion in Q3 2025, $1.3 billion in Q2 2025, and $1.1 billion in Q1 2025.